Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Apatinib with Rosuvastatin and Metformin in Solid Tumors
NCT04428086Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Rivoceranib in solid tumor (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve (AUC0-last, AUC0-inf). Started Jul 2020; status: completed.
02
Drugs
Rivoceranib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04428086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428086.